Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)

Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)

Show other versions (1)

Background The relevance of the cause of kidney disease to prognosis among patients with chronic kidney disease is uncertain. Study Design Observational study. Settings and Participants 6,245 nondialysis participants in the Study of Heart and Renal Protection (SHARP). Predictor Baseline cause of kid...

תיאור מלא

מידע ביבליוגרפי
Main Authors:	Haynes, R, Staplin, N, Emberson, J, Herrington, W, Tomson, C, Agodoa, L, Tesar, V, Levin, A, Lewis, D, Reith, C, Baigent, C, Landray, M
פורמט:	Journal article
יצא לאור:	2014

פריטים דומים

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).
מאת: Haynes, R, et al.
יצא לאור: (2014)

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
מאת: Staplin, N, et al.
יצא לאור: (2015)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
מאת: Herrington, WG, et al.
יצא לאור: (2023)

Smoking and adverse outcomes in patients With CKD: the Study of Heart and Renal Protection (SHARP)
מאת: Emberson, J, et al.
יצא לאור: (2016)

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
מאת: Staplin, N, et al.
יצא לאור: (2016)

Conventional and genetic evidence on the association between adiposity and CKD
מאת: Zhu, P, et al.
יצא לאור: (2020)

Impact of CKD on household income
מאת: Morton, R, et al.
יצא לאור: (2017)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
מאת: Herrington, W, et al.
יצא לאור: (2016)

Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
מאת: Lamprea-Montealegre, J, et al.
יצא לאור: (2019)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
מאת: Zhu, P, et al.
יצא לאור: (2020)

The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.
מאת: Herrington, W, et al.
יצא לאור: (2014)

Evidence for the prevention and treatment of stroke in dialysis patients
מאת: Herrington, W, et al.
יצא לאור: (2014)

Effects of lowering LDL cholesterol on progression of kidney disease.
מאת: Haynes, R, et al.
יצא לאור: (2014)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
מאת: Mihaylova, B, et al.
יצא לאור: (2019)

Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
מאת: Baigent, C, et al.
יצא לאור: (2010)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the study of heart and renal protection
מאת: Reith, C, et al.
יצא לאור: (2017)

Impact of CKD on Household Income
מאת: Rachael L. Morton, et al.
יצא לאור: (2018-05-01)

Benefits of lowering cholesterol in chronic kidney disease Reply
מאת: Baigent, C, et al.
יצא לאור: (2011)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
מאת: Mafham, M, et al.
יצא לאור: (2017)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
מאת: Storey, B, et al.
יצא לאור: (2018)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection
מאת: C. Reith, et al.
יצא לאור: (2017-05-01)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
מאת: Herrington, W, et al.
יצא לאור: (2018)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
מאת: Herrington, W, et al.
יצא לאור: (2022)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
מאת: Schlackow, I, et al.
יצא לאור: (2017)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
מאת: Zhu, P, et al.
יצא לאור: (2020)

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
מאת: Mayne, K, et al.
יצא לאור: (2024)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
מאת: Storey, B, et al.
יצא לאור: (2017)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
מאת: Mayne, KM, et al.
יצא לאור: (2024)

Study of Heart and Renal Protection (SHARP).
מאת: Baigent, C, et al.
יצא לאור: (2003)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
מאת: Baigent, C, et al.
יצא לאור: (2011)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
מאת: Baigent, C, et al.
יצא לאור: (2011)

Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology
מאת: Staplin, N, et al.
יצא לאור: (2022)

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
מאת: Cholesterol Treatment Trialists' Collaboration, et al.
יצא לאור: (2016)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
מאת: Haynes, R, et al.
יצא לאור: (2018)

Serum free light chains and the risk of ESRD and death in CKD.
מאת: Haynes, R, et al.
יצא לאור: (2011)

Serum free light chains and the risk of ESRD and death in CKD
מאת: Haynes, R, et al.
יצא לאור: (2011)

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
מאת: Mayne, K, et al.
יצא לאור: (2023)

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
מאת: Staplin, N, et al.
יצא לאור: (2021)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
מאת: Staplin, N, et al.
יצא לאור: (2023)

Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study.
מאת: Landray, M, et al.
יצא לאור: (2010)